Professor Andrew Sewell

Teams and roles for Andrew Sewell

Professor, Division of Infection and Immunity. Mechanisms of Immunity Theme Lead, Systems Immunity Research Institute.
School of Medicine

If you are a patient, thank you for reaching out to me after seeing the article about our research. It is at an early stage and although we are hopeful that these new cells will be therapeutically valuable, they have yet to be tested and approved for clinical trials. For more support please contact a cancer support group in your local area.

My research focuses on how T-cells recognise and respond to disease, with particular emphasis on the antigens they detect and the T-cell receptors (TCRs) that enable this recognition. A major theme of our work is understanding unconventional forms of T-cell recognition that extend beyond classical HLA-restricted immunity, and exploiting these discoveries to understand and treat human disease.

Our research spans cancer, infection, autoimmunity, transplantation and vaccination, combining fundamental discovery with the development of new approaches to identify disease-reactive T-cells and their targets. We are particularly interested in discovering T-cells that recognise shared features of diseased cells and understanding the molecular mechanisms that allow them to distinguish these cells from healthy tissue.

A list of my publications is available here: https://scholar.google.com/citations?user=pc2BYZsAAAAJ

Date
Type

2026

Caillaud, M. E. et al. 2026. Optimised procurement of cancer-reactive T-cell receptors from clinical samples. Immunotherapy Advances (10.1093/immadv/ltag009)
Goto, Y. et al., 2026. A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer. Frontiers in Immunology 17 1750569. (10.3389/fimmu.2026.1750569)
Thomas, H. et al. 2026. Protocol for MR1-ligand cross-linking to discover metabolite antigens by proteomics. STAR Protocols 7 (1) 104399. (10.1016/j.xpro.2026.104399)
Sewell, A. 2026. A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling. arXiv (10.64898/2026.02.19.706929)

2025

Schmidlin, T. et al., 2025. MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens. Cell Reports Methods 101120. (10.1016/j.crmeth.2025.101120)
Ferrari, M. et al., 2025. Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies. Nature Communications 16 (1) 1103. (10.1038/s41467-025-56396-7)
Dolton, G. et al., 2025. MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.. The Journal of Clinical Investigation 135 (1) e181895. (10.1172/JCI181895)

2024

Schwartz, J. C. et al., 2024. A genome assembly and transcriptome atlas of the inbred Babraham pig to illuminate porcine immunogenetic variation.. Immunogenetics 76 , pp.361-380. (10.1007/s00251-024-01355-7)
Dolton, G. et al. 2024. HLA A*24:02-restricted T-cell receptors cross recognise bacterial and preproinsulin peptides in type 1 diabetes. Journal of Clinical Investigation 134 (18) e164535. (10.1172/JCI164535)
Ferrari, M. et al., 2024. Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies. Nature Communications 15 (1) 1583. (10.1038/s41467-024-45854-3)

2023

Chen, Y. et al. 2023. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Reports 42 (8) 112827. (10.1016/j.celrep.2023.112827)
Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)

2022

Goncharov, M. et al., 2022. VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2. Nature Methods 19 (9), pp.1017–1019. (10.1038/s41592-022-01578-0)
Dolton, G. et al. 2022. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell 185 (16), pp.2936-2951. (10.1016/j.cell.2022.07.002)
Martini, V. et al., 2022. Spatial, temporal and molecular dynamics of swine influenza virus-specific CD8 tissue resident memory T cells. Mucosal Immunology 15 (3), pp.428–442. (10.1038/s41385-021-00478-4)

2021

Clement, M. et al. 2021. CD8 coreceptor-mediated focusing can reorder the agonist hierarchy of peptide ligands recognized via the T cell receptor. Proceedings of the National Academy of Sciences 118 (29) e2019639118. (10.1073/pnas.2019639118)
Crowther, M. D. and Sewell, A. K. 2021. The burgeoning role of MR1-restricted T-cells in infection, cancer and autoimmune disease. Current Opinion in Immunology 69 , pp.10-17. (10.1016/j.coi.2020.12.002)
Edmans, M. et al., 2021. Magnitude and kinetics of T cell and antibody responses during H1N1pdm09 infection in inbred Babraham pigs and outbred pigs. Frontiers in Immunology 11 604913. (10.3389/fimmu.2020.604913)
Martini, V. et al., 2021. Simultaneous aerosol and intramuscular immunization with influenza vaccine induces powerful protective local T cell and systemic antibody immune responses in pigs. Journal of Immunology 206 (2) ji2001086. (10.4049/jimmunol.2001086)

2020

Attaf, M. et al. 2020. Cytomegalovirus-mediated T cell receptor repertoire perturbation is present in early life. Frontiers in Immunology 11 1587. (10.3389/fimmu.2020.01587)
Hopkins, J. R. et al. 2020. Peptide cargo tunes a network of correlated motions in human leukocyte antigens. FEBS Journal 287 (17), pp.3777-3793. (10.1111/febs.15278)
Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32 (2) 107885. (10.1016/j.celrep.2020.107885)
Tarbe, M. et al., 2020. Synthesis and biological evaluation of hapten-clicked analogues of the antigenic peptide Melan‐A/MART‐126(27L)‐35. ChemMedChem 15 (9), pp.799-807. (10.1002/cmdc.202000038)
Yeo, L. et al., 2020. Circulating β cell‐specific CD8+ T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes. Clinical and Experimental Immunology 199 (3), pp.263-277. (10.1111/cei.13391)
Crowther, M. D. et al. 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21 , pp.178 - 185. (10.1038/s41590-019-0578-8)
Whalley, T. et al. 2020. GPU-accelerated discovery of pathogen-derived molecular mimics of a T-cell insulin epitope. Frontiers in Immunology 11 296. (10.3389/fimmu.2020.00296)
Bagaev, D. V. et al., 2020. VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium. Nucleic Acids Research 48 (D1), pp.D1057-D1062. gkz874. (10.1093/nar/gkz874)

2019

MacLachlan, B. J. et al., 2019. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry 294 (52), pp.20246-20258. (10.1074/jbc.RA119.009437)
Kim, A. et al., 2019. LILRB1 blockade enhances bispecific T cell engager antibody-induced tumor cell killing by effector CD8+ T cells. Journal of Immunology 203 (4), pp.1076-1087. (10.4049/jimmunol.1801472)
Madura, F. et al. 2019. TCR-induced alteration of primary MHC peptide anchor residue. European Journal of Immunology 49 (7), pp.1052-1066. (10.1002/eji.201948085)
Galloway, S. A. E. et al. 2019. Peptide super-agonist enhances T-cell responses to melanoma. Frontiers in Immunology 10 319. (10.3389/fimmu.2019.00319)

2018

Attaf, M. et al. 2018. Major TCR repertoire perturbation by immunodominant HLA-B*44:03 - restricted CMV - specific T cells. Frontiers in Immunology 2539. (10.3389/fimmu.2018.02539)
Sewell, A. K. and Legut, M. 2018. Designer T-cells and T-cell receptors for customised cancer immunotherapies. Current Opinion in Pharmacology 41 , pp.96-103. (10.1016/j.coph.2018.05.005)
Yeo, L. et al., 2018. Autoreactive T effector memory differentiation mirrors b cell function in type 1 diabetes. Journal of Clinical Investigation 128 (8), pp.3460-3474. (10.1172/JCI120555)
Zhao, X. et al., 2018. Nonstimulatory peptide?MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling. Nature Communications 9 2716. (10.1038/s41467-018-05288-0)
Dolton, G. et al. 2018. Optimized peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells. Frontiers in Immunology 9 1378. (10.3389/fimmu.2018.01378)
Tungatt, K. et al. 2018. Induction of influenza-specific local CD8 T-cells in the respiratory tract after aerosol delivery of vaccine antigen or virus in the Babraham inbred pig. PLoS Pathogens 14 (5) e1007017. (10.1371/journal.ppat.1007017)
Holland, C. J. et al. 2018. In silico and structural analyses demonstrate that intrinsic protein motions guide T cell receptor complementarity determining region loop flexibility. Frontiers in Immunology 9 674. (10.3389/fimmu.2018.00674)
Miles, J. J. et al. 2018. Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation 128 (4), pp.1569-1580. (10.1172/JCI91512)
Rius, C. et al., 2018. Peptide-MHC class 1 tetramers can fail to detect relevant functional T cell clonotypes and underestimate antigen-reactive T cell populations. Journal of Immunology 200 (7), pp.2263-2279. (10.4049/jimmunol.1700242)
Bovay, A. et al., 2018. T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus. European Journal of Immunology 48 (2), pp.258-272. (10.1002/eji.201747082)
Legut, M. et al. 2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131 (3), pp.311-322. (10.1182/blood-2017-05-787598)
Shugay, M. et al., 2018. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Research 46 (D1), pp.D419-D427. (10.1093/nar/gkx760)

2017

Maciocia, P. M. et al., 2017. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nature Medicine 23 , pp.1416-1423. (10.1038/nm.4444)
Cole, D. K. et al. 2017. Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope. Frontiers in Immunology 8 1503. (10.3389/fimmu.2017.01503)
Jones, N. et al., 2017. Metabolic adaptation of human CD4+ and CD8+ T-Cells to T-Cell receptor-mediated stimulation. Frontiers in Immunology 8 1516. (10.3389/fimmu.2017.01516)
Donia, M. et al., 2017. PD-1+ polyfunctional T cells dominate the periphery after tumour-infiltrating lymphocyte therapy for cancer. Clinical Cancer Research 23 (19), pp.5779-5788. (10.1158/1078-0432.CCR-16-1692)
Fuller, A. et al. 2017. Thermal stability of heterotrimeric pMHC proteins as determined by circular dichroism spectroscopy. Bio-protocol 7 (13), pp.-. e2366. (10.21769/BioProtoc.2366)
MacLachlan, B. J. et al. 2017. Using X-ray crystallography, biophysics, and functional assays to determine the mechanisms governing T-cell receptor recognition of cancer antigens. Journal of Visualized Experiments (120) e54991. (10.3791/54991)
Cole, D. K. et al. 2017. Structural mechanism underpinning cross-reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase reverse transcriptase. Journal of Biological Chemistry 292 (3), pp.802-813. (10.1074/jbc.M116.741603)
Tan, M. et al., 2017. HLA class I-redirected anti-tumour CD4+T-cells require a higher TCR binding affinity for optimal activity than CD8+T-cells. Clinical and Experimental Immunology 187 (1), pp.124-137. (10.1111/cei.12828)

2016

Pageon, S. V. et al., 2016. Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proceedings of the National Academy of Sciences 113 (37), pp.E5454-E5463. (10.1073/pnas.1607436113)
Hanson, W. M. et al., 2016. Reversible oligonucleotide chain blocking enables bead capture and amplification of T-Cell receptor alpha and beta chain mRNAs. Journal of the American Chemical Society 138 (35), pp.11073-11076. (10.1021/jacs.6b04465)
Stadinski, B. D. et al., 2016. Hydrophobic CDR3 residues promote the development of self-reactive T cells. Nature Immunology 17 , pp.946-955. (10.1038/ni.3491)
Laugel, B. et al. 2016. Engineering of isogenic cells deficient for MR1 with a CRISPR/Cas9 lentiviral system: tools to study microbial antigen processing and presentation to human MR1-restricted T cells. Journal of Immunology 197 (3), pp.971-982. (10.4049/jimmunol.1501402)
Szomolay, B. et al. 2016. Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors. Immunology and Cell Biology 94 (6), pp.573-582. (10.1038/icb.2016.12)
Caucheteux, S. M. et al. 2016. Polypropylene sulfide nanoparticle p24 vaccine promotes dendritic cell-mediated specific immune responses against HIV-1. Journal of Investigative Dermatology 136 (6), pp.1172-1181. (10.1016/j.jid.2016.01.033)
Cole, D. K. et al. 2016. Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. Journal of Clinical Investigation 126 (6), pp.2191-2204. (10.1172/JCI85679)
Bianchi, V. et al. 2016. A molecular switch abrogates glycoprotein 100 (gp100) T-cell Receptor (TCR) targeting of a human melanoma antigen. Journal of Biological Chemistry 291 (17), pp.8951-8959. (10.1074/jbc.M115.707414)
Theaker, S. M. et al. 2016. T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones. Journal of Immunological Methods 430 , pp.43-50. (10.1016/j.jim.2016.01.014)
Attaf, M. and Sewell, A. K. 2016. Disease etiology and diagnosis by TCR repertoire analysis goes viral. European Journal of Immunology 46 (11), pp.2516-2519. (10.1002/eji.201646649)
Meermeier, E. W. et al., 2016. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nature Communications 7 12506. (10.1038/ncomms12506)
Tsai, M. et al., 2016. Paediatric non-progression following grandmother-to-child HIV transmission. Retrovirology 13 (1), pp.65. (10.1186/s12977-016-0300-y)

2015

Holland, C. J. et al., 2015. Enhanced detection of antigen-specific CD4+ T cells using altered peptide flanking residue peptide-MHC class II multimers. Journal of Immunology 195 (12), pp.5827-5836. (10.4049/jimmunol.1402787)
Dolton, G. M. et al. 2015. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology 146 (1), pp.11-22. (10.1111/imm.12499)
Motozono, C. et al. 2015. Distortion of the major histocompatibility complex class I binding groove to accommodate an insulin-derived 10-Mer peptide. Journal of Biological Chemistry 290 (31), pp.18924-18933. (10.1074/jbc.M114.622522)
Gilham, D. E. et al., 2015. Adoptive t-cell therapy for cancer in the United Kingdom: a review of activity for the British Society of Gene and Cell Therapy Annual Meeting 2015. Human Gene Therapy 26 (5), pp.276-285. (10.1089/hum.2015.024)
Skowera, A. et al., 2015. β-Cell-specific CD8 T Cell phenotype in Type 1 diabetes reflects chronic autoantigen exposure. Diabetes 64 (3), pp.916-925. (10.2337/db14-0332)
Madura, F. et al., 2015. Structural basis for ineffective T-cell responses to MHC anchor residue-improved 'heteroclitic' peptides. European Journal of Immunology 45 (2), pp.584-591. (10.1002/eji.201445114)
Tungatt, K. et al. 2015. Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs. Journal of Immunology 194 (1), pp.463-474. (10.4049/jimmunol.1401785)
Attaf, M. , Huseby, E. and Sewell, A. K. 2015. αβ T cell receptors as predictors of health and disease. Cellular and Molecular Immunology 12 , pp.391-399. (10.1038/cmi.2014.134)
Attaf, M. et al. 2015. The T cell antigen receptor: the Swiss army knife of the immune. Clinical and Experimental Immunology 181 (1), pp.1-18. (10.1111/cei.12622)
Kløverpris, H. N. et al., 2015. A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape. Retrovirology 12 (1) 20. (10.1186/s12977-015-0149-5)
Knight, R. R. et al., 2015. A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells. Clinical and Experimental Immunology 179 (1), pp.100-107. (10.1111/cei.12436)
Legut, M. , Cole, D. and Sewell, A. K. 2015. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy. Cellular and Molecular Immunology 12 , pp.656-668. (10.1038/cmi.2015.28)
Motozono, C. et al. 2015. Clonotypically similar hybrid ab T cell receptors can exhibit markedly different surface expression, antigen specificity and cross-reactivity. Clinical and Experimental Immunology 180 (3), pp.560-570. (10.1111/cei.12610)
Neller, M. A. et al., 2015. Naive CD8+ T-cell precursors display structured TCR repertoires and composite antigen-driven selection dynamics. Immunology and Cell Biology 93 , pp.625-633. (10.1038/icb.2015.17)
Straetemans, T. et al., 2015. Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. Molecular Therapy 23 (2), pp.396-406. (10.1038/mt.2014.215)

2014

Tan, M. et al. 2014. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+T cells. Clinical and Experimental Immunology 180 (2), pp.255-270. (10.1111/cei.12570)
Stepanek, O. et al., 2014. Coreceptor scanning by the T cell receptor provides a mechanism for T cell tolerance. Cell 159 (2), pp.333-345. (10.1016/j.cell.2014.08.042)
Bhati, M. et al., 2014. The versatility of the αβ T-cell antigen receptor. Protein Science 23 (3), pp.260-272. (10.1002/pro.2412)
Dolton, G. M. et al. 2014. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clinical and Experimental Immunology 177 (1), pp.47-63. (10.1111/cei.12339)
Motozono, C. et al. 2014. Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01. The Journal of Immunology 192 (7), pp.3428-3434. (10.4049/jimmunol.1302667)

2013

van den Berg, H. A. et al., 2013. Cellular-level versus receptor-level response threshold hierarchies in T-cell activation. Frontiers in Immunology 4 250. (10.3389/fimmu.2013.00250)
Motozono, C. et al., 2013. CD8+ T cell cross-reactivity profiles and HIV-1 immune escape towards an HLA-B35-restricted immunodominant Nef epitope. PLoS ONE 8 (6) e66152. (10.1371/journal.pone.0066152)
Xu, W. et al., 2013. The nucleocapsid protein of rift valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS ONE 8 (3) e59210. (10.1371/journal.pone.0059210)
Eukeruche-Makinde, J. et al., 2013. Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood -New York- 121 (7), pp.1112-1123. (10.1182/blood-2012-06-437202)
Cole, D. et al. 2013. T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions. Journal of Biological Chemistry 289 (2), pp.628-638. (10.1074/jbc.M113.522110)
Challier, J. et al., 2013. Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8+ T-cell priming capacity. Immunology 138 (4), pp.402-410. (10.1111/imm.12053)
Ekeruche, J. et al. 2013. Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood 121 (7), pp.1112-1123. (10.1182/blood-2012-06-437202)
Knight, R. R. et al., 2013. Human β-cell killing by autoreactive preproinsulin-specific cd8 t cells is predominantly granule-mediated with the potency dependent upon t-cell receptor avidity. Diabetes 62 (1), pp.205-213. (10.2337/db12-0315)
Madura, F. et al. 2013. T-cell receptor specificity maintained by altered thermodynamics. Journal of Biological Chemistry 288 (26), pp.18766-18775. (10.1074/jbc.M113.464560)
Pentier, J. M. , Sewell, A. K. and Miles, J. J. 2013. Advances in T-Cell Epitope Engineering. Frontiers in Immunology 4 133. (10.3389/fimmu.2013.00133)
Welton, J. et al. 2013. Monocytes and γδ T cells control the acute phase response to intravenous zoledronate: insights from a phase IV safety trial. Journal of Bone and Mineral Research (JBMR) 28 (3), pp.464-471. (10.1002/jbmr.1797)

2012

Ekeruche-Makinde, J. et al., 2012. T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. Journal of Biological Chemistry 287 (44), pp.37269-37281. (10.1074/jbc.M112.386409)
Cole, D. K. et al. 2012. The molecular determinants of CD8 co-receptor function. Immunology 137 (2), pp.139-148. (10.1111/j.1365-2567.2012.03625.x)
Holland, C. J. et al. 2012. Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Scientific Reports 2 629. (10.1038/srep00629)
Liddy, N. et al., 2012. Monoclonal TCR-redirected tumor cell killing. Nature Medicine 18 (6), pp.980-987. (10.1038/nm.2764)
Cole, D. et al. 2012. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications 3 665. (10.1038/ncomms1665)
Wooldridge, L. et al. 2012. A single autoimmune T cell receptor recognizes more than a million different peptides. Journal of Biological Chemistry 287 (2), pp.1168-1177. (10.1074/jbc.M111.289488)
Bridgeman, J. S. et al. 2012. Structural and biophysical determinants of ab T-cell antigen recognition. Immunology 135 (1), pp.9-18. (10.1111/j.1365-2567.2011.03515.x)
Bulek, A. M. et al. 2012. Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes. Nature Immunology 13 (3), pp.283-289. (10.1038/ni.2206)
Bulek, A. M. et al. 2012. TCR/pMHC optimized protein crystallization screen. Journal of Immunological Methods 382 (1-2), pp.203-210. (10.1016/j.jim.2012.06.007)
Matthews, P. C. et al., 2012. Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single gag epitope. Journal of Virology 86 (23), pp.12643-12654. (10.1128/JVI.01381-12)
Sewell, A. K. 2012. Why must T cells be cross-reactive?. Nature Reviews Immunology 12 (9), pp.669-677. (10.1038/nri3279)

2011

Clement, M. et al. 2011. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. The Journal of Immunology 187 (2), pp.654-663. (10.4049/jimmunol.1003941)
Laugel, B. F. et al. 2011. The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells. Journal of Leukocyte Biology 90 (6), pp.1089-1099. (10.1189/jlb.0611316)
Miles, K. M. et al. 2011. Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Molecular Immunology 48 (4), pp.728-732. (10.1016/j.molimm.2010.11.004)

2010

Cole, D. et al. 2010. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. The Journal of Immunology 185 (4), pp.2600-2610. (10.4049/jimmunol.1000629)
Wooldridge, L. et al. 2010. CD8 controls T cell cross-reactivity. The Journal of Immunology 185 (8), pp.4625-4632. (10.4049/jimmunol.1001480)
Chen, J. et al., 2010. Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor. The Journal of Immunology 184 (4), pp.1829-1839. (10.4049/jimmunol.0902103)
Miles, J. J. et al. 2010. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathogens 6 (11) e1001198. (10.1371/journal.ppat.1001198)
Schaubert, K. L. et al., 2010. Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. European Journal of Immunology 40 (7), pp.1950-1962. (10.1002/eji.200940079)
Walker, L. J. , Sewell, A. K. and Klenerman, P. 2010. T cell sensitivity and the outcome of viral infection. Clinical and Experimental Immunology 159 (3), pp.245-255. (10.1111/j.1365-2249.2009.04047.x)
Wooldridge, L. et al. 2010. MHC Class I molecules with superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. Journal of Immunology 184 (7), pp.3357-3366. (10.4049/jimmunol.0902398)

2009

Borbulevych, O. Y. et al., 2009. T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity 31 (6), pp.885-896. (10.1016/j.immuni.2009.11.003)
Hoffman, M. et al., 2009. Novel tetramer technology for the detection of high affinity CD8 T cells [Conference poster abstract]. Retrovirology 6 (S3) P409. (10.1186/1742-4690-6-S3-P409)
Lissina, A. et al., 2009. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. Journal of Immunological Methods 340 (1), pp.11-24. (10.1016/j.jim.2008.09.014)
Choudhuri, K. et al., 2009. Peptide-Major Histocompatibility Complex Dimensions Control Proximal Kinase-Phosphatase Balance during T Cell Activation. Journal of Biological Chemistry 284 (38), pp.26096-26105. (10.1074/jbc.M109.039966)
Cole, D. et al. 2009. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. Journal of Biological Chemistry 284 (40) 27281-27289. (10.1074/jbc.M109.022509)
Horlock, C. et al., 2009. ELISPOT and functional T cell analyses using HLA mono-specific target cells. Journal of Immunological Methods 350 (1-2), pp.150-160. (10.1016/j.jim.2009.08.011)
Jo, J. et al., 2009. Analysis of CD8+ T-Cell-Mediated Inhibition of Hepatitis C Virus Replication Using a Novel Immunological Model. Gastroenterology 136 (4), pp.1391-1401. (10.1053/j.gastro.2008.12.034)
Wooldridge, L. et al. 2009. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 126 (2), pp.147-164. (10.1111/j.1365-2567.2008.02848.x)

2008

Melenhorst, J. J. et al., 2008. Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. Journal of Immunological Methods 338 (1-2), pp.31-39. (10.1016/j.jim.2008.07.008)
Chattopadhyay, P. K. et al., 2008. Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+T cells with peptide-major histocompatibility complex class I tetramers. Cytometry Part A 73A (11), pp.1001-1009. (10.1002/cyto.a.20642)
Cole, D. et al. 2008. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Molecular Immunology 45 (9), pp.2700-2709. (10.1016/j.molimm.2007.12.009)
Kasprowicz, V. et al., 2008. Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. Journal of Clinical Investigation 118 (3), pp.1143-1153. (10.1172/JCI33082)
Scriba, T. J. et al., 2008. The staphyloccous aureus eap protein activates expression of proinflammatory cytokines. Infection and Immunity 76 (5), pp.2164-2168. (10.1128/IAI.01699-07)
Skowera, A. et al., 2008. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation 118 (10), pp.3390-3402. (10.1172/JCI35449)
Varela-Rohena, A. et al., 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Medicine 14 (12), pp.1390-1395. (10.1038/nm.1779)
Weichsel, R. et al., 2008. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clinical Cancer Research 14 (8), pp.2484-2491. (10.1158/1078-0432.CCR-07-4393)

2007

Laugel, B. F. et al. 2007. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotxic T lymphocyte activation and tetramer properties. The Journal of Biological Chemistry 282 (33), pp.23799-22810. (10.1074/jbc.M700976200)
Cole, D. et al. 2007. Human TCR-binding affinity is governed by MHC class restriction. The Journal of Immunology 178 (9), pp.5727-5734. (10.4049/jimmunol.178.9.5727)
Wooldridge, L. et al. 2007. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. European Journal of Immunology 37 (5), pp.1323-1333. (10.1002/eji.200636765)
Gostick, E. et al., 2007. Functional and biophysical characterization of an HLA-A*6801-restricted HIV-specific T cell receptor. European Journal of Immunology 37 (2), pp.479-486. (10.1002/eji.200636243)
Boulter, J. M. et al. 2007. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology 37 (3), pp.798-806. (10.1002/eji.200636743)
Laugel, B. et al., 2007. CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. European Journal of Immunology 37 (4), pp.905-913. (10.1002/eji.200636718)
Schaubert, K. L. et al., 2007. Availability of a diversely Avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 gag p2419-27 epitope. The Journal of Immunology 178 (12), pp.7756-7766. (10.4049/jimmunol.178.12.7756)
Yuan, F. et al., 2007. Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex. Acta Crystallographica Section F: Structural Biology and Crystallization Communications 63 (9), pp.758-760. (10.1107/S1744309107037244)

2006

Wooldridge, L. et al. 2006. Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. European Journal of Immunology 36 (7), pp.1847-1855. (10.1002/eji.200635886)
Laugel, B. , Price, D. and Sewell, A. K. 2006. On the path to TCR-directed therapeutics. Nature Biotechnology 24 (6), pp.615-616. (10.1038/nbt0606-615b)

2005

Price, D. et al. 2005. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. Journal of Experimental Medicine 202 (10), pp.1349-61. (10.1084/jem.20051357)
Wooldridge, L. et al. 2005. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. The Journal of Biological Chemistry 280 (30), pp.27491-27501. (10.1074/jbc.M500555200)
Sewell, A. et al. 2005. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine 201 (6), pp.891-902. (10.1084/jem.20041455)
Laugel, B. et al., 2005. Design of soluble recombinant T Cell receptors for antigen targeting and T cell inhibition. Journal of Biological Chemistry 280 (3), pp.1882-1892. (10.1074/jbc.M409427200)
Hewitt, R. E. et al., 2005. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clinical and Experimental Immunology 139 (1), pp.101-111. (10.1111/j.1365-2249.2005.02665.x)
Rezvani, K. et al., 2005. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.. Clinical Cancer Research 11 (24), pp.8799-8807. (10.1158/1078-0432.CCR-05-1314)

2004

Green, A. E. et al., 2004. Recognition of nonpeptide antigens by human Vγ9Vδ2 T cells requires contact with cells of human origin. Clinical & Experimental Immunology 136 (3), pp.472-482. (10.1111/j.1365-2249.2004.02472.x)

2003

Wooldridge, L. et al. 2003. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 171 , pp.6650-60.

2002

Glick, M. et al., 2002. Novel CD8+ T cell antagonists based on 2-Microglobulin. Journal of Biological Chemistry 277 (23), pp.20840-20846. (10.1074/jbc.M201819200)
Kelleher, A. D. , Sewell, A. K. and Price, D. 2002. Dyslipidemia due to retroviral protease inhibitors [Letter]. Nature Medicine 8 (4), pp.308. (10.1038/nm0402-308a)

2001

Sewell, A. K. et al. 2001. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 14 (5), pp.591-602. (10.1016/S1074-7613(01)00133-9)
Oxenius, A. et al., 2001. Cross-staining of cytotoxic T lymphocyte populations with peptide-MHC class I multimers of natural HIV-1 variant antigens. AIDS 15 (1), pp.121-122. (10.1097/00002030-200101050-00018)
Purbhoo, M. A. et al., 2001. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor chain. Journal of Biological Chemistry 276 (35), pp.32786-32792. (10.1074/jbc.M102498200)
Sewell, A. K. and Price, D. 2001. Dendritic cells and transmission of HIV-1. Trends in Immunology 22 (4), pp.173-175. (10.1016/S1471-4906(01)01866-X)

2000

Oxenius, A. et al., 2000. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 97 (7), pp.3382-3387. (10.1073/pnas.97.7.3382)

1999

Price, D. et al. 1999. Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunology Today 20 (5), pp.212-216. (10.1016/S0167-5699(99)01447-4)
Sewell, A. K. et al. 1999. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8. Nature Medicine 5 , pp.399-404. (10.1038/7398)

1998

Lewis, J. W. et al., 1998. HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin. European Journal of Immunology 28 , pp.3214-3220.
Price, D. et al. 1998. Antigen-specific release of b-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Current Biology 8 (6), pp.355-358. (10.1016/S0960-9822(98)70138-1)

1997

Sewell, A. K. et al. 1997. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. European Journal of Immunology 27 (9), pp.2323-2329. (10.1002/eji.1830270929)
Price, D. et al. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proceedings of the National Academy of Sciences 94 (5), pp.1890-1895. (10.1073/pnas.94.5.1890)

Cardiff and Kumamoto researchers uncover how a common probiotic, when given alongside immunotherapy, can activate tumour-killing immune cells.

International team identifies immune pathway that may explain how probiotics influence cancer treatment outcomes

24 March 2026

Cardiff and Kumamoto researchers uncover how a common probiotic, when given alongside immunotherapy, can activate tumour-killing immune cells.

Cardiff University researchers have discovered a new anticancer T-cell subtype, which could help our immune system tackle cancer in the future.

New anticancer T-cell type discovered

02 January 2025

Cardiff University researchers have discovered a new anticancer T-cell subtype, which could help our immune system tackle cancer in the future.

Bacterial infection can induce an immune response that leads to type-1 diabetes, according to Cardiff University researchers.

Bacteria triggers type-1 diabetes

18 September 2024

Bacterial infection can induce an immune response that leads to type-1 diabetes, according to Cardiff University researchers.

Multipronged T-cells discovered which “might be associated with complete cancer remission” say Cardiff team

Superior T-cell discovered in cancer survivors

24 July 2023

Multipronged T-cells discovered which “might be associated with complete cancer remission” say Cardiff team

Cardiff University scientists urge monitoring of ‘viral escape’ – and warn vaccines may need altering

Study pinpoints SARS-CoV-2 Spike mutation that ‘escapes’ killer T-cells generated by infection and vaccination

05 August 2022

Cardiff University scientists urge monitoring of ‘viral escape’ – and warn vaccines may need altering

Professor Andrew Sewell and team win funding from Cancer Grand Challenge

Cardiff University researchers to join £20m global study to tackle cancer in children

16 June 2022

Professor Andrew Sewell and team win funding from Cancer Grand Challenge

Cardiff University study describes unconventional immune cell which could open up treatment of wide range of cancers in all patients

Discovery of new T-cell raises prospect of ‘universal’ cancer therapy

20 January 2020

Cardiff University study describes unconventional immune cell which could open up treatment of wide range of cancers in all patients

Pig immune system study gives researchers new method of developing flu vaccines

Pig immunology comes of age

18 May 2018

Pig immune system study gives researchers new method of developing flu vaccines

Cardiff scientists create world’s first synthetic, non-biologic vaccine

First step in development of pill-based vaccines

12 March 2018

Cardiff scientists create world’s first synthetic, non-biologic vaccine 

Genome editing enhances T-cells for cancer immunotherapy

Improved method of engineering T-cells to attack cancer

17 November 2017

Genome editing enhances T-cells for cancer immunotherapy

Unique approach to treatment of rare and aggressive blood cancers

Targeting cancer without destroying healthy T-cells

14 November 2017

Unique approach to treatment of rare and aggressive blood cancers

Contact Details

[email protected]
+44 29206 87055

Cardiff and Kumamoto researchers uncover how a common probiotic, when given alongside immunotherapy, can activate tumour-killing immune cells.

International team identifies immune pathway that may explain how probiotics influence cancer treatment outcomes

24 March 2026

Cardiff University researchers have discovered a new anticancer T-cell subtype, which could help our immune system tackle cancer in the future.

New anticancer T-cell type discovered

02 January 2025

Bacterial infection can induce an immune response that leads to type-1 diabetes, according to Cardiff University researchers.

Bacteria triggers type-1 diabetes

18 September 2024